# Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

> **NCT02815033** · PHASE2 · COMPLETED · sponsor: **The European Uro-Oncology Group** · enrollment: 66 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Enzalutamide
- **PROCEDURE:** 11C or 18F-Choline PET/CT
- **PROCEDURE:** Whole body MRI
- **PROCEDURE:** Bone scan

## Key facts

- **NCT ID:** NCT02815033
- **Lead sponsor:** The European Uro-Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2020-06
- **Final completion:** 2020-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2022-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02815033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02815033, "Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02815033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*